I agree, you know Ibalizumab posted their trial fi

I agree, you know Ibalizumab posted their trial first in 2016 and have been approved for over a year now. Leronlimab first posted the trial to clinicaltrials.gov in 2015, and the fda keep adding hoops for us to jump through even though the efficacy is almost twice for leronlimab than IZ at the 325mg dose. The only reason I can think of is IZ works on both while leronlimab for R5. But why should the R5 group, which is the majority, have to be punished with an inferior product, with a high cost plus IV twice a month while leronlimab waits on approval, just because IZ happens to work on the other group as well? Crazy the difference made for IZ. All the others for unmet need had a much higher bar than them as well.